SEC Form 4 · accession 0001562180-19-000148

Sienna Biopharmaceuticals, Inc. · SNNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Paul F. Lizzul

Officer — Chief Medical Officer

Period of report

Jan 1, 2019

Accepted (ET)

Jan 3, 2019 · 6:16 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001656328

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jan 1, 2019	A	45,000	—	A	142,583	D
Common Stock^F3	holding	—	—		—	10,557	I	See Footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Options (Right to buy)	$2.32	Jan 1, 2019	A	14,904	A	Jan 1, 2019	Jan 1, 2029	Common Stock	14,904	14,904	D
Stock Options (Right to buy)^F4	$2.32	Jan 1, 2019	A	22,500	A	—	Jan 1, 2029	Common Stock	22,500	22,500	D
Stock Options (Right to buy)^F5	$2.32	Jan 1, 2019	A	22,500	A	—	Jan 1, 2029	Common Stock	22,500	45,000	D

Explanation of responses

F1Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
F2Includes a total of 2,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
F3The shares are directly held by the Lizzul Living Trust.
F4Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F5Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.